Form 4: Zoetis CEO Kristin Peck Reports Stock Option and Restricted Stock Unit Grants
SEC Form 4 Filing
Zoetis Inc. CEO Kristin Peck reports the grant of stock options and restricted stock units (RSUs) under the company's equity and incentive plans.
Summary
- Kristin C. Peck, CEO of Zoetis Inc., filed a Form 4 detailing changes in beneficial ownership of the company's securities.
- The report includes the grant of 21,745 restricted stock units (RSUs) on February 19, 2025, which vest in three equal installments on the first, second, and third anniversaries of the grant date.
- The report also includes the grant of 84,711 stock options on February 19, 2025, which vest in three equal installments on the first, second, and third anniversaries of the grant date and expire ten years from the grant date.
- The report also details existing holdings of RSUs and stock options granted in previous years.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management interests with shareholders.
Positives
- The grant of stock options and RSUs aligns the CEO's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Future Outlook
The vesting schedules for the RSUs and stock options extend over the next three years, incentivizing continued service and performance.
Industry Context
Stock option and RSU grants are a common practice in the pharmaceutical industry to incentivize and retain top executives.
Comparison to Industry Standards
- Companies like Eli Lilly, Merck, and Pfizer also utilize stock options and RSUs as part of their executive compensation packages.
- The vesting schedules and grant sizes are generally comparable to industry standards for companies of similar size and market capitalization.
Stakeholder Impact
- The grants align management's interests with shareholders, potentially driving long-term value creation.
- Employees may view the grants as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 02/08/2022 | 54,751 options granted at an exercise price of $201.30 per option. |
| 02/08/2023 | One-third of previously granted RSUs vest and are settled in shares of Zoetis Inc. common stock. |
| 02/06/2024 | One-third of previously granted RSUs vest and are settled in shares of Zoetis Inc. common stock. |
| 02/19/2025 | Date of the reported transaction: grant of RSUs and stock options. |
| 02/19/2025 | Grant of 21,745 Restricted Stock Units. |
| 02/19/2025 | Grant of 84,711 Stock Options with an exercise price of $156.64. |
| 02/19/2025 | One-third of each RSU will vest and be settled in shares of Zoetis Inc. common stock on the first, second and third anniversaries of the date of grant. |
| 02/19/2025 | One-third of each option will vest on the first, second and third anniversaries of the date of grant. |
| 02/21/2025 | Date of signature for the Form 4 filing. |
| 02/19/2035 | Each option expires on the tenth anniversary of the date of grant. |
Keywords
Zoetis, Kristin Peck, Stock Options, Restricted Stock Units, RSU, ZTS, Equity Incentive Plan, Form 4, Beneficial Ownership, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.